A Randomized, Placebo-Controlled, Phase II Study of Tetomilast in Active Ulcerative Colitis

Medicine and Dentistry

• Placebo 100%
• Disease Activity 50%
• Patient 40%
• Ulcerative Colitis 30%
• Phase II Trials 20%
• Post-Hoc Analysis 20%
• Development 10%
• Adverse Event 10%
• Spontaneous Remission 10%
• Gastrointestinal Distress 10%
• Leukocyte 10%
• Serositis 10%
• Nausea and Vomiting 10%
• Superoxide 10%
• Intention-to-Treat Analysis 10%
• Cytokine Release 10%
• Phosphodiesterase IV 10%

INIS

• diseases 50%
• patients 40%
• reduction 20%
• populations 10%
• production 10%
• inflammation 10%
• cytokines 10%
• safety 10%
• investigations 10%
• leukocytes 10%
• doses 10%
• phosphodiesterases 10%
• nausea 10%
• vomiting 10%
• thiazoles 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Tetomilast 90%
• Disease Activity 50%
• Ulcerative Colitis 30%
• Adverse Event 10%
• Remission 10%
• Nausea and Vomiting 10%
• Superoxide 10%
• Gastrointestinal Symptom 10%
• Phosphodiesterase IV 10%